AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30702403
Drug: Bleaching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching treatment with refrigerated storage (5°C)
Trial: 30702403
Drug: Consistency test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistency test of bleaching gels
Trial: 28034564
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml black tea
Trial: 24065124
Drug: PEG‐IFN/RBV combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN/RBV combination therapy
Trial: 12552319
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose solutions (Group 2)
Trial: 10601539
Drug: Ornithine alpha-ketoglutarate
RxNorm normalized name: ornithine alpha-ketoglutarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornithine alpha-ketoglutarate (20 g/day)
Trial: 24083027
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (twice a week for eight weeks)
Trial: 9037323
Drug: Phenylephrine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (1 microgram/kg) infusion
Trial: 9037323
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (1 microgram/kg) infusion
Trial: 8584604
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion (5% sodium chloride at 0.06 ml/kg/min)
Trial: 8584604
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (0.9% sodium chloride at 0.06 ml/kg/min)
Trial: 2670535
Drug: ACC‐9653 (PHT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC‐9653 (PHT prodrug) administered intravenously (i.v.)
Trial: 2670535
Drug: ACC‐9653 (PHT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC‐9653 (PHT prodrug) administered intramuscularly (i.m.)
Trial: 25814428
Drug: Six different
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six different moistening solutions (specific solutions not detailed)
Trial: 24372155
Drug: Fast ice
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast ice cream consumption (5 min)
Trial: 24372155
Drug: Slow ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow ice cream consumption (30 min)
Trial: 19221352
Drug: Rapid-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-acting insulin analogues (insulin lispro)
Trial: 19221352
Drug: Rapid-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-acting insulin analogues (insulin aspart)
Trial: 19221352
Drug: Rapid-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-acting insulin analogues (insulin lispro) in type 2 diabetes
Trial: 19221352
Drug: Rapid-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-acting insulin analogues (insulin aspart) in type 2 diabetes
Trial: 19221352
Drug: Long-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting insulin analogues (insulin glargine)
Trial: 19221352
Drug: Long-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting insulin analogues (insulin detemir)
Trial: 19221352
Drug: Long-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting insulin analogues (insulin glargine) in type 2 diabetes
Trial: 19221352
Drug: Long-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting insulin analogues (insulin detemir) in type 2 diabetes
Trial: 15378838
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of plutonium
Trial: 15378838
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of gamma rays
Trial: 12600112
Drug: Aprotinin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (3 x 10^6 added to the priming solution of ECC)
Trial: 12600112
Drug: Amrinone combined
RxNorm normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amrinone combined with aprotinin (3 x 10^6 aprotinin + bolus of 1 mg/kg amrinone followed by 8 micrograms/(kg.min) maintenance infusion)
Trial: 3099486
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 5 mg (30 mg/day)
Trial: 3099486
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 20 mg (120 mg/day)
Trial: 3099486
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 40 mg (240 mg/day)
Trial: 3099486
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 80 mg (480 mg/day)
Trial: 3099486
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of ISDN 80 mg (480 mg/day) for 4 weeks
Trial: 3099486
Drug: Nitroglycerin 2.6
RxNorm normalized name: nitroglycerin 2.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin 2.6 mg (single dose)
Trial: 3099486
Drug: Nitroglycerin 6.5
RxNorm normalized name: nitroglycerin 6.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin 6.5 mg
Trial: 3099486
Drug: Nitroglycerin 10
RxNorm normalized name: nitroglycerin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin 10 mg
Trial: 3099486
Drug: Nitroglycerin 20
RxNorm normalized name: Nitroglycerin 20 mg/g cutaneous ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin 20 mg
Trial: 3099486
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin 5 cm2 patch
Trial: 3099486
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin 10 cm2 patch
Trial: 3099486
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin 20 cm2 patch
Trial: 29458406
Drug: Pyriproxyfen/spinosad combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyriproxyfen/spinosad combination treatment of permanent water storage containers
Trial: 19879596
Drug: Colesevelam 1.875
RxNorm normalized name: colesevelam 1.875 g oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 1.875 g/d
Trial: 16839823
Drug: contact‐control delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: contact‐control delayed treatment group
Trial: 8534533
Drug: 3 L
RxNorm normalized name: D3 Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 L of balanced electrolyte/polyethylene glycol solution (PEG)
Trial: 8534533
Drug: Senna laxatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senna laxatives and sodium phosphate enemas
Trial: 7004480
Drug: Chymoral (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chymoral (exact dosage and duration not specified)
Trial: 31908066
Drug: SR-dexamphetamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR-dexamphetamine (2 x 30 mg/day)
Trial: 30422953
Drug: Immunosuppressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressant therapy
Trial: 29211123
Drug: Morse Taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morse Taper (MT) implants
Trial: 24936090
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment consisting of a leaflet on health and lifestyle
Trial: 14756387
Drug: Regitine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regitine 40 mg tablet formulation
Trial: 14756387
Drug: Vasomax 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasomax 40 mg tablet formulation
Trial: 9776327
Drug: Antiepileptic drug
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drug treatment (AEDs)
Trial: 9776327
Drug: Post-drug discontinuation
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-drug discontinuation assessment
Trial: 3053457
Drug: Prophylactic systemic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic systemic antibiotics (PSA) in a conventional hospital room (PSA group, 101 patients)
Trial: 31702883
Drug: Difelikefalin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difelikefalin (0.5 μg/kg)
Trial: 27397551
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy without antifungal prophylaxis
Trial: 25938241
Drug: Guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-based cognitive-behavioral therapy (iCBT) for 9 weeks
Trial: 20089204
Drug: B-vitamin supplements
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin supplements (folate 1 mg, vitamin B12 500 microg, vitamin B6 10 mg)
Trial: 19127918
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of tablet Caltrate with Vit D2
Trial: 16859470
Drug: Intrarectal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal and anal EMLA cream (subgroup A)
Trial: 16859470
Drug: Ultrasound gel
RxNorm normalized name: Ultrasound gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound gel as placebo (subgroup B)
Trial: 14516238
Drug: Internet-driven treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-driven treatment of posttraumatic stress
Trial: 1633720
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg hidrosmin, 1 capsule 3-times daily for 45 days
Trial: 1633720
Drug: Placebo, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 capsule 3-times daily for 45 days
Trial: 31372762
Drug: Metabolomic profiling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolomic profiling in patients with myasthenia gravis (MG)
Trial: 27473188
Drug: Ultra-micronized palmitoylethanolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-micronized palmitoylethanolamide (um-PEA) 600 mg twice a day
Trial: 23512705
Drug: IBHB (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBHB (300 mg, twice daily)
Trial: 20637968
Drug: Crushed pellets
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed pellets from MS-sNT (60 mg morphine/2.4 mg naltrexone)
Trial: 20637968
Drug: Naltrexone solution
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone solution (2.4 mg)
Trial: 20637968
Drug: Whole MS-sNT
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole MS-sNT capsule (60 mg morphine/2.4 mg naltrexone)
Trial: 20637968
Drug: Naltrexone solution
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone solution
Trial: 17252564
Drug: Chemotherapy intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy intensification (Capizzi II)
Trial: 7325345
Drug: Fentanyl epidurally
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl epidurally (0.1‐0.2 mg diluted with 0.9% saline solution)
Trial: 7325345
Drug: Systemic opiate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic opiate therapy by intramuscular application of piritramide (Dipidolor, 15‐25 mg)
Trial: 23514242
Drug: Real Time
RxNorm normalized name: MENTHOL 15 mg in 1 g TOPICAL CREAM [Real Time Pain Relief Foot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real Time Medication Monitoring system (RTMM) with tailored text-messages
Trial: 21291439
Drug: Parents in
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents in treatment for depression
Trial: 16430412
Drug: Caudal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ketamine (0.25 mg.kg(‐1)) plus lidocaine (2%, 2 mg.kg(‐1))
Trial: 16430412
Drug: Caudal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ketamine (0.25 mg.kg(‐1)) plus tramadol (1 mg.kg(‐1))
Trial: 12830445
Drug: Short daily
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short daily hemodialysis (n = 11)
Trial: 12830445
Drug: Conventional thrice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional thrice-weekly hemodialysis (n = 22)
Trial: 9337184
Drug: Heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000 U bolus followed by 1000 to 1200 U/h)
Trial: 9337184
Drug: Low-dose hirulog
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hirulog (0.125 mg/kg bolus followed by 0.25 mg x kg(‐1) x h(‐1) for 12 hours then 0.125 mg x kg(‐1) x h(‐1))
Trial: 9337184
Drug: High-dose hirulog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hirulog (0.25 mg/kg bolus followed by 0.5 mg x kg(‐1) x h(‐1) for 12 hours then 0.25 mg x kg(‐1) x h(‐1))
Trial: 9337184
Drug: Low-dose hirulog
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hirulog
Trial: 9337184
Drug: High-dose hirulog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hirulog
Trial: 30374692
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg IV CRH
Trial: 24378745
Drug: d‐amphetamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine (0.3 mg/kg, p.o.)
Trial: 15122555
Drug: Viewing a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viewing a treatment simulation before surgery
Trial: 15122555
Drug: Standard presurgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard presurgical consultation without treatment simulation
Trial: 11476123
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 mg for first two injections; 5 mg for third injection)
Trial: 11476123
Drug: Lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2 mg for first two injections; 1 mg for third injection)
Trial: 11476123
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo for first two injections; olanzapine 10 mg for third injection)
Trial: 7840527
Drug: CAV-E (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV-E (cyclophosphamide 1000 mg/m2, adriamycin 50 mg/m2, vincristine 2 mg, plus etoposide 100 mg/m2)
Trial: 7840527
Drug: CAV-T (teniposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV-T (teniposide 60 mg/m2 on days 2, 3, 4)
Trial: 7840527
Drug: alpha-interferon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-interferon (3 x 10(6) I.U., i.m. daily x 9 months)
Trial: 3295323
Drug: Cefixime (CFIX)
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime (CFIX) 100 mg b.i.d.
Trial: 3295323
Drug: Cefroxadine (CXD)
RxNorm normalized name: cefradine
DrugBank: Cefroxadine (DB11367)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefroxadine (CXD) 250 mg t.i.d.
Trial: 28741624
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (30 μg ethinyl estradiol/0.15 mg levonorgestrel)
Trial: 25947930
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg sublingual melatonin
Trial: 25947930
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg sublingual melatonin
Trial: 25947930
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg sublingual melatonin
Trial: 21038019
Drug: Opt‐FP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opt‐FP 400 µg
Trial: 10714758
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin therapy via pen-injector (Novopen II)
Trial: 10714758
Drug: Patient-mixed insulin
RxNorm normalized name: insulin aspart protamine, human / insulin aspart, human Injectable Suspension [NovoLog Mix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-mixed insulin therapy via conventional syringe
Trial: 8234642
Drug: Nightguard vital
RxNorm normalized name: Vital-Chlor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nightguard vital bleaching (3-hour exposure with replenishment of test solution hourly)
Trial: 8234642
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (glycerin)
Trial: 29641362
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch (175 mg) applied to umbilical trocar site
Trial: 29641362
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no lidocaine patch)
Trial: 24261547
Drug: Family-centred music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-centred music therapy (FCMT) for 16 weeks in addition to early intervention programmes
Trial: 18721703
Drug: Intracameral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral moxifloxacin 0.5% (250 mug/0.050 mL)
Trial: 12855265
Drug: Bio-chemotherapy (bio-CT)
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-chemotherapy (bio-CT)
Trial: 10568212
Drug: DHEP lecithin
RxNorm normalized name: Lecithin
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP lecithin gel (1.3% DHEP and 2.4% lecithin)
Trial: 10568212
Drug: DHEP gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP gel (without lecithin)
Trial: 10568212
Drug: DHEP lecithin
RxNorm normalized name: Lecithin
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP lecithin gel
Trial: 24345165
Drug: D2/D3 dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2/D3 dopamine receptor binding measured using [F-18]fallypride
Trial: 17726460
Drug: Mouse TYR
RxNorm normalized name: Tyr
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouse TYR DNA vaccine followed by human TYR DNA vaccine (3 injections each, 100, 500, and 1,500 microg DNA/injection, IM every 3 weeks)
Trial: 17726460
Drug: Human TYR
RxNorm normalized name: IMMUNOGLOBULIN G1 (DE-450-LYSINE), ANTI-(HUMAN TYROSINE KINASE RECEPTOR AXL) (HUMAN-MUS MUSCULUS MONOCLONAL BA301 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL BA301 .KAPPA.-CHAIN, DIMER, THIOETHER WITH N-(((4-((N-(6-(3-MERCAPTO-2,5-DIOXO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human TYR DNA vaccine followed by mouse TYR DNA vaccine (3 injections each, 100, 500, and 1,500 microg DNA/injection, IM every 3 weeks)
Trial: 17726460
Drug: Both mouse
RxNorm normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both mouse and human TYR DNA vaccines
Trial: 15241748
Drug: Home-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based physical therapy (PT) program (prehabilitation)
Trial: 11756645
Drug: Natural L-glutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural L-glutamine (0.5 g x kg(‐1) x d(‐1))
Trial: 25228838
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D group (cholecalciferol 2,000 IU/day + calcium 200 mg/day)
Trial: 25228838
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (calcium 200 mg/day)
Trial: 11783186
Drug: Neiyi 1+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neiyi 1+ pill (TCM group)
Trial: 8724034
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (loviride + lamivudine + zidovudine)
Trial: 8724034
Drug: Double combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double combination (loviride + zidovudine)
Trial: 30010698
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch (RS2) 45 g/d for 12 weeks
Trial: 27087153
Drug: 0.005 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005 mg/kg cisatracurium
Trial: 27087153
Drug: 0.01 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg/kg cisatracurium